Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech)

A Japanese man experienced three episodes of hypovolemic shock and was diagnosed with systemic capillary leak syndrome (SCLS). He developed SCLS exacerbation 2 days after receiving a second dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine, 1 year after the third episode. After fluid therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Akiyama, Yutaro, Inagaki, Takeshi, Morioka, Shinichiro, Kusano, Eiji, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372265/
https://www.ncbi.nlm.nih.gov/pubmed/37081683
http://dx.doi.org/10.2169/internalmedicine.1682-23
_version_ 1785078335197413376
author Akiyama, Yutaro
Inagaki, Takeshi
Morioka, Shinichiro
Kusano, Eiji
Ohmagari, Norio
author_facet Akiyama, Yutaro
Inagaki, Takeshi
Morioka, Shinichiro
Kusano, Eiji
Ohmagari, Norio
author_sort Akiyama, Yutaro
collection PubMed
description A Japanese man experienced three episodes of hypovolemic shock and was diagnosed with systemic capillary leak syndrome (SCLS). He developed SCLS exacerbation 2 days after receiving a second dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine, 1 year after the third episode. After fluid therapy and albumin administration, we initiated terbutaline and theophylline prophylaxis for SCLS. A literature review revealed that SCLS attacks often occur 1-2 days after the second COVID-19 vaccination. Patients with a history of SCLS should avoid COVID-19 vaccination and be carefully monitored for 1-2 days if they receive the vaccine.
format Online
Article
Text
id pubmed-10372265
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-103722652023-07-28 Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) Akiyama, Yutaro Inagaki, Takeshi Morioka, Shinichiro Kusano, Eiji Ohmagari, Norio Intern Med Case Report A Japanese man experienced three episodes of hypovolemic shock and was diagnosed with systemic capillary leak syndrome (SCLS). He developed SCLS exacerbation 2 days after receiving a second dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine, 1 year after the third episode. After fluid therapy and albumin administration, we initiated terbutaline and theophylline prophylaxis for SCLS. A literature review revealed that SCLS attacks often occur 1-2 days after the second COVID-19 vaccination. Patients with a history of SCLS should avoid COVID-19 vaccination and be carefully monitored for 1-2 days if they receive the vaccine. The Japanese Society of Internal Medicine 2023-04-21 2023-07-01 /pmc/articles/PMC10372265/ /pubmed/37081683 http://dx.doi.org/10.2169/internalmedicine.1682-23 Text en Copyright © 2023 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Akiyama, Yutaro
Inagaki, Takeshi
Morioka, Shinichiro
Kusano, Eiji
Ohmagari, Norio
Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech)
title Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech)
title_full Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech)
title_fullStr Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech)
title_full_unstemmed Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech)
title_short Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech)
title_sort exacerbations of idiopathic systemic capillary leak syndrome following bnt162b2 mrna covid-19 vaccine (pfizer-biontech)
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372265/
https://www.ncbi.nlm.nih.gov/pubmed/37081683
http://dx.doi.org/10.2169/internalmedicine.1682-23
work_keys_str_mv AT akiyamayutaro exacerbationsofidiopathicsystemiccapillaryleaksyndromefollowingbnt162b2mrnacovid19vaccinepfizerbiontech
AT inagakitakeshi exacerbationsofidiopathicsystemiccapillaryleaksyndromefollowingbnt162b2mrnacovid19vaccinepfizerbiontech
AT moriokashinichiro exacerbationsofidiopathicsystemiccapillaryleaksyndromefollowingbnt162b2mrnacovid19vaccinepfizerbiontech
AT kusanoeiji exacerbationsofidiopathicsystemiccapillaryleaksyndromefollowingbnt162b2mrnacovid19vaccinepfizerbiontech
AT ohmagarinorio exacerbationsofidiopathicsystemiccapillaryleaksyndromefollowingbnt162b2mrnacovid19vaccinepfizerbiontech

Ejemplares similares